{ "items": [ "\n\n
\n \n 12 January 2016\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nMelioidosis, a difficult to diagnose deadly bacterial disease, is likely to be present in many more countries than previously thought, reports a paper published online today in the journal Nature Microbiology. The study predicts that melioidosis is present in 79 countries, including 34 that have never reported the disease.
\n \n\n\n \n 27 December 2015\n \n
\n\n \n\n \n\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n \n \nAlthough the Wang Pha clinic was established to treat malaria, it hasn't had a malaria case at all in several days. Now, patients come with other ailments or to visit the maternity ward. \"When no one is worried, that's when we have to worry,\" said professor Francois Nosten, director of the Shoklo Malaria Research Unit, which includes Wang Pha and four other clinics along the Thai-Myanmar border.
\n \n\n\n \n 11 November 2015\n \n
\n\n \n\n \n\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n \n \nIn the past few months, the Shoklo Malaria Research Unit (SMRU) has begun a campaign to make pregnant Karen women and their husbands aware of the importance of pre-conceptual folate to prevent neural tube defects in newborns.
\n \n\n\n \n 4 September 2015\n \n
\n\n \n\n \n\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Shoklo Malaria Research Unit (SMRU) led Malaria Elimination Task Force has undertaken mass drug administration campaigns in Eastern Karen State, Myanmar in areas with a high sub microscopic Plasmodium falciparum parasite prevalence.
\n \n\n\n \n 31 August 2015\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Bill & Melinda Gates Foundation has approved a three-year grant that will lead to an expansion of the pharmacometric research group within MORU\u2019s Department of Clinical Pharmacology.
\n \n\n\n \n 27 April 2015\n \n
\n\n \n\n \n\n \n \n \n \n MOCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nFearing that drug resistant malaria will reach Africa, Prof Fran\u00e7ois Nosten and his team are among those scientists who are scrambling to stop it while they still can. Drug resistance to artemisinin has been steadily increasing in Southeast Asia. Having emerged in Cambodia in 2007, it since has been recorded in Thailand, Vietnam and Myanmar. Artemisinin is the last remaining effective drug against the resistant falciparum strain, and there are no suitable replacements yet.
\n \n\n\n \n 14 April 2015\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nAn unconventional clinical trial design might have advantages over classical trials for testing treatments for Ebola virus disease (EVD), suggests a study published this week in PLOS Medicine. The work of an international team led by John Whitehead of Lancaster University, UK and Ben Cooper (Oxford University, UK, and Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand) provides much-needed data to inform a debate on the scientific and ethical justification for non-randomized EVD trials that has taken place in the editorial pages of a number of medical journals in past months.
\n \n\n\n \n 20 February 2015\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nBangkok / Oxford (UK), 20 February 2015 - Resistance to the antimalarial drug artemisinin is established in Myanmar and has reached within 25km of the Indian border, a study published today in Lancet Infectious Diseases reports. Artemisinin resistance threatens to follow the same historical trajectory from Southeast Asia to the Indian subcontinent as seen in the past with other antimalarial medicines.
\n \n\n\n \n 19 January 2015\n \n
\n\n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n \n \nLargest genome-wide study of parasite provides clearest picture yet of genetic changes driving artemisinin resistance\r\nartemisinin-genetics-resistance. Hinxton, Cambridge, UK, 19 January 2015 \u2013 The largest genome-wide association study to date of the malaria parasite Plasmodium falciparum unveils a complex genetic architecture that enables the parasite to develop resistance to our most effective antimalarial drug, artemisinin.
\n \n\n